{"id":60108,"date":"2024-02-28T06:34:28","date_gmt":"2024-02-28T06:34:28","guid":{"rendered":"https:\/\/medsname.com\/cerecetam\/"},"modified":"2026-05-01T10:49:15","modified_gmt":"2026-05-01T10:49:15","slug":"cerecetam","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/cerecetam\/","title":{"rendered":"Cerecetam"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:18px 22px;margin:0 0 24px 0;border-radius:4px;\">\n<h3 class=\"wp-block-heading\" style=\"margin:0 0 8px 0;font-size:16px;font-weight:700;\">\u26a1 Rychl\u00e1 odpov\u011b\u010f \u2014 Co je Cerecetam?<\/h3>\n<p style=\"margin:0;\"><strong>Cerecetam<\/strong> je peror\u00e1ln\u00ed <strong>tableta<\/strong> obsahuj\u00edc\u00ed <strong>piracetam<\/strong> (400 mg, 800 mg) \u2014 p\u016fvodn\u00ed \u201cnootropikum\u201d z \u0159ady pyrrolidonov\u00fdch deriv\u00e1t\u016f. Pou\u017e\u00edv\u00e1 se pro: <strong>kortik\u00e1ln\u00ed myoklonus<\/strong> (indikace podlo\u017een\u00e1 d\u016fkazy FDA\/EMA), <strong>v\u011bkem podm\u00edn\u011bn\u00e9ho poklesu kognitivn\u00edch funkc\u00ed<\/strong>, <strong>kognitivn\u00ed p\u0159\u00edznaky po c\u00e9vn\u00ed mozkov\u00e9 p\u0159\u00edhod\u011b nebo traumatick\u00e9m poran\u011bn\u00ed mozku<\/strong>, <strong>z\u00e1vra\u0165 centr\u00e1ln\u00edho p\u016fvodu<\/strong>, a <strong>dyslexie u d\u011bt\u00ed<\/strong> (indikace v EU, spolu se strukturovanou n\u00e1pravou). D\u00e1vkov\u00e1n\u00ed pro dosp\u011bl\u00e9: <strong>2,4\u20134,8 g\/den<\/strong> ve 2\u20133 d\u00edl\u010d\u00edch d\u00e1vk\u00e1ch (kognitivn\u00ed); 7,2\u201324 g\/den pro kortik\u00e1ln\u00ed myoklonus. U\u017e\u00edvejte s j\u00eddlem nebo bez j\u00eddla. N\u00e1stup \u00fa\u010dinku: 4\u20138 t\u00fddn\u016f pro kognitivn\u00ed p\u0159\u00ednosy. Obecn\u011b dob\u0159e sn\u00e1\u0161en; \u010dast\u00e9 ne\u017e\u00e1douc\u00ed \u00fa\u010dinky: nespavost, podr\u00e1\u017ed\u011bnost, p\u0159ib\u00fdv\u00e1n\u00ed na v\u00e1ze, bolest hlavy. <strong>Kontraindikov\u00e1no u t\u011b\u017ek\u00e9ho ren\u00e1ln\u00edho selh\u00e1n\u00ed a Huntingtonovy choroby<\/strong>. Neschv\u00e1leno americkou FDA \u2014 prod\u00e1v\u00e1no jako l\u00e9k na p\u0159edpis ve v\u011bt\u0161in\u011b Evropy, Asie a Latinsk\u00e9 Ameriky.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f4f8fb;border:1px solid #d8e3eb;padding:12px 16px;margin:16px 0;border-radius:4px;font-size:14px;\">\n<strong>Co z\u00edsk\u00e1te s MedsBase:<\/strong> V\u00fdrobce certifikovan\u00fd WHO-GMP \u00b7 Diskr\u00e9tn\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 doprava \u00b7 V\u00edce ne\u017e 1 400 ov\u011b\u0159en\u00fdch <a href=\"https:\/\/medsbase.com\/cs\/reviews\/\">recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed <a href=\"https:\/\/medsbase.com\/cs\/medsbase-re-shipment-assurance-policy\/\"><strong>Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n<h3>Pro\u010d objedn\u00e1vat z MedsBase<\/h3>\n<p>Na\u0161e generick\u00e9 l\u00e9ky poch\u00e1zej\u00ed od v\u00fdrobc\u016f certifikovan\u00fdch WHO-GMP a jsou expedov\u00e1ny po cel\u00e9m sv\u011bt\u011b v diskr\u00e9tn\u00edm, nen\u00e1padn\u00e9m balen\u00ed \u2013 na vn\u011bj\u0161\u00ed stran\u011b bal\u00edku nen\u00ed uveden n\u00e1zev l\u00e9ku. Platby kartou jsou sm\u011brov\u00e1ny prost\u0159ednictv\u00edm regulovan\u00e9ho procesoru (popisky na v\u00fdpisu zahrnuj\u00ed regulovan\u00e9ho procesora plateb kartou \u2013 nikdy \u201cMedsBase\u201d nebo n\u00e1zev l\u00e9ku). P\u0159ij\u00edm\u00e1me tak\u00e9 kryptom\u011bny a bankovn\u00ed p\u0159evody SEPA. Ka\u017ed\u00e1 objedn\u00e1vka je zaji\u0161t\u011bna na\u0161\u00ed politikou p\u0159eposl\u00e1n\u00ed.<\/p>\n<h2 class=\"wp-block-heading\">Co je Cerecetam?<\/h2>\n<p>Cerecetam je peror\u00e1ln\u00ed piracetam <strong>tableta<\/strong> dostupn\u00fd v d\u00e1vk\u00e1ch 400 mg, 800 mg. Piracetam (2-oxo-1-pyrrolidinacetamid) je cyklick\u00fd deriv\u00e1t GABA syntetizovan\u00fd spole\u010dnost\u00ed UCB v roce 1964 a prvn\u00ed z\u00e1stupce <strong>racetamov\u00e9 t\u0159\u00eddy nootropik<\/strong>. Je registrov\u00e1n ve v\u011bt\u0161in\u011b Evropy, Latinsk\u00e9 Ameriky a Asie jako l\u00e9k na p\u0159edpis pro <strong>kognitivn\u00ed poruchy<\/strong>, <strong>kortik\u00e1ln\u00ed myoklonus<\/strong> a <strong>vertiga<\/strong>. Nen\u00ed schv\u00e1len FDA ve Spojen\u00fdch st\u00e1tech, ale je st\u00e1le \u0161iroce pou\u017e\u00edv\u00e1n mezin\u00e1rodn\u011b.<\/p>\n<p>Cerecetam je dod\u00e1v\u00e1n v\u00fdrobcem certifikovan\u00fdm WHO-GMP a je bioekvivalentn\u00ed s origin\u00e1ln\u00edm piracetamem (Nootropil\u00ae, UCB).<\/p>\n<h2 class=\"wp-block-heading\">Jak Cerecetam funguje?<\/h2>\n<p>Mechanismus piracetamu je neobvykl\u00fd a po 60 letech klinick\u00e9ho pou\u017eit\u00ed nen\u00ed zcela objasn\u011bn:<\/p>\n<ul>\n<li><strong>Modulace fluidity membr\u00e1n<\/strong> \u2014 piracetam interaguje s fosfolipidov\u00fdmi hlavn\u00edmi skupinami, obnovuje fluiditu membr\u00e1n u st\u00e1rnouc\u00edch nebo po\u0161kozen\u00fdch neuron\u016f. To m\u016f\u017ee b\u00fdt z\u00e1kladem jeho preferen\u010dn\u00edho \u00fa\u010dinku u kognitivn\u011b posti\u017een\u00fdch oproti zdrav\u00e9 populaci.<\/li>\n<li><strong>Zlep\u0161en\u00e1 mozkov\u00e1 mikrocirkulace<\/strong> \u2014 sni\u017euje rigiditu erytrocyt\u016f a agregaci trombocyt\u016f, m\u00edrn\u011b zlep\u0161uje mozkov\u00fd pr\u016ftok krve bez zm\u011bny syst\u00e9mov\u00e9ho krevn\u00edho tlaku.<\/li>\n<li><strong>Modulace AMPA receptor\u016f<\/strong> \u2014 pozitivn\u00ed alosterick\u00fd \u00fa\u010dinek na glutam\u00e1tov\u00e9 AMPA receptory, zvy\u0161uje dlouhodobou potenciaci v anim\u00e1ln\u00edch modelech.<\/li>\n<li><strong>Pos\u00edlen\u00ed cholinergn\u00edho syst\u00e9mu<\/strong> \u2014 zv\u00fd\u0161en\u00fd p\u0159\u00edjem cholinu s vysokou afinitou a synt\u00e9za acetylcholinu v n\u011bkter\u00fdch oblastech mozku.<\/li>\n<li><strong>Ochrana mitochondri\u00ed<\/strong> \u2014 zachov\u00e1v\u00e1 produkci ATP p\u0159i hypoxick\u00e9m stresu.<\/li>\n<\/ul>\n<p>Na rozd\u00edl od sedativn\u00edch antikonvulziv piracetam <strong>neovliv\u0148uje GABA-receptory, nem\u00e1 sedativn\u00ed \u00fa\u010dinek, nezp\u016fsobuje z\u00e1vislost<\/strong> a nevede k otupen\u00ed kognitivn\u00edch funkc\u00ed. U zdrav\u00fdch mlad\u00fdch dosp\u011bl\u00fdch je obvykle ne\u00fa\u010dinn\u00fd, zat\u00edmco u pacient\u016f s kognitivn\u00edm posti\u017een\u00edm, c\u00e9vn\u00edm onemocn\u011bn\u00edm mozku nebo kortik\u00e1ln\u00ed myokloni\u00ed p\u0159in\u00e1\u0161\u00ed v\u00fdrazn\u011bj\u0161\u00ed prosp\u011bch.<\/p>\n<h2 class=\"wp-block-heading\">Pou\u017eit\u00ed a indikace<\/h2>\n<ul>\n<li><strong>Kortik\u00e1ln\u00ed myoklonie<\/strong> \u2014 nejl\u00e9pe prok\u00e1zan\u00e1 indikace; piracetam je uzn\u00e1vanou l\u00e9\u010dbou, \u010dasto jako dopln\u011bk k jin\u00fdm antikonvulziv\u016fm<\/li>\n<li><strong>V\u011bkem podm\u00edn\u011bn\u00e9 kognitivn\u00ed posti\u017een\u00ed<\/strong> \u2014 m\u00edrn\u00e9 kognitivn\u00ed posti\u017een\u00ed, vaskul\u00e1rn\u00ed kognitivn\u00ed posti\u017een\u00ed<\/li>\n<li><strong>Kognitivn\u00ed zotaven\u00ed po c\u00e9vn\u00ed mozkov\u00e9 p\u0159\u00edhod\u011b<\/strong> \u2014 zejm\u00e9na af\u00e1zie po mozkov\u00e9 p\u0159\u00edhod\u011b v lev\u00e9 hemisf\u00e9\u0159e (indikace v EU; podpora n\u011bkter\u00fdmi RCT)<\/li>\n<li><strong>Kognitivn\u00ed n\u00e1sledky traumatick\u00e9ho po\u0161kozen\u00ed mozku<\/strong><\/li>\n<li><strong>Z\u00e1vrat\u011b centr\u00e1ln\u00edho p\u016fvodu<\/strong> \u2014 zlep\u0161uje vestibul\u00e1rn\u00ed kompenzaci<\/li>\n<li><strong>Dyslexie u d\u011bt\u00ed &gt;7 let<\/strong> \u2014 indikace v EU, pou\u017e\u00edv\u00e1 se jako dopln\u011bk k strukturovan\u00e9 n\u00e1prav\u011b<\/li>\n<li><strong>Prevence srpkovit\u00e9 krize<\/strong> \u2014 mimo indikaci, mechanismus spo\u010d\u00edv\u00e1 v reologick\u00e9m \u00fa\u010dinku na erytrocyty<\/li>\n<li><strong>Mimo indikaci:<\/strong> obecn\u00e9 nootropikum \/ kognitivn\u00ed enhancement (omezen\u00e9 d\u016fkazy u zdrav\u00fdch mlad\u00fdch dosp\u011bl\u00fdch)<\/li>\n<\/ul>\n<p>Cerecetam je <strong>ne<\/strong> l\u00e9k prvn\u00ed volby u: Alzheimerovy demence (inhibitory cholinester\u00e1zy a memantin maj\u00ed siln\u011bj\u0161\u00ed d\u016fkazy), deprese s kognitivn\u00edmi p\u0159\u00edznaky (nejprve l\u00e9\u010dit depresi) nebo poruchy pozornosti.<\/p>\n<h2 class=\"wp-block-heading\">D\u00e1vkov\u00e1n\u00ed Cerecetamu a zp\u016fsob u\u017e\u00edv\u00e1n\u00ed<\/h2>\n<p>Dostupn\u00e9 s\u00edly Cerecetamu: <strong>400 mg, 800 mg<\/strong>.<\/p>\n<p><strong>Standardn\u00ed d\u00e1vkov\u00e1n\u00ed pro dosp\u011bl\u00e9 podle indikace:<\/strong><\/p>\n<ul>\n<li><strong>V\u011bkem podm\u00edn\u011bn\u00e9 kognitivn\u00ed posti\u017een\u00ed \/ vaskul\u00e1rn\u00ed demence \/ po c\u00e9vn\u00ed mozkov\u00e9 p\u0159\u00edhod\u011b:<\/strong> 2,4\u20134,8 g\/den ve 2\u20133 d\u00edl\u010d\u00edch d\u00e1vk\u00e1ch. Mnoho pacient\u016f reaguje na 2,4 g\/den (nap\u0159. 800 mg t\u0159ikr\u00e1t denn\u011b).<\/li>\n<li><strong>Kortik\u00e1ln\u00ed myoklonus:<\/strong> Za\u010dn\u011bte s 7,2 g\/den ve 2\u20133 d\u00e1vk\u00e1ch. Zvy\u0161ujte o 4,8 g\/den ka\u017ed\u00e9 3\u20134 dny a\u017e na maximum 24 g\/den. Udr\u017eovac\u00ed d\u00e1vka je nejni\u017e\u0161\u00ed mno\u017estv\u00ed, kter\u00e9 kontroluje myoklonus.<\/li>\n<li><strong>Z\u00e1vrat\u011b:<\/strong> 2,4\u20134,8 g\/den ve 2\u20133 d\u00e1vk\u00e1ch po dobu 8\u201312 t\u00fddn\u016f; n\u00e1sledn\u011b p\u0159ehodno\u0165te.<\/li>\n<li><strong>D\u011bti s dyslexi\u00ed (&gt;7 let):<\/strong> 3,2 g\/den ve 2 rozd\u011blen\u00fdch d\u00e1vk\u00e1ch spolu se strukturovanou n\u00e1pravnou v\u00fdukou.<\/li>\n<li><strong>Porucha funkce ledvin:<\/strong> \u00daprava d\u00e1vky podle clearance kreatininu \u2014 CrCl 50\u201379: standardn\u00ed d\u00e1vka; CrCl 30\u201349: polovi\u010dn\u00ed d\u00e1vka; CrCl &lt;30: nedoporu\u010duje se.<\/li>\n<\/ul>\n<h3 class=\"wp-block-heading\">Jak spr\u00e1vn\u011b u\u017e\u00edvat Cerecetam<\/h3>\n<ol>\n<li><strong>Dvakr\u00e1t a\u017e t\u0159ikr\u00e1t denn\u011b v pravideln\u00fdch intervalech.<\/strong> Polo\u010das je 4\u20135 hodin. Intervaly mezi d\u00e1vkami jsou d\u016fle\u017eit\u00e9 u myoklonu; m\u00e9n\u011b kritick\u00e9 u kognitivn\u00edho u\u017eit\u00ed.<\/li>\n<li><strong>S j\u00eddlem nebo bez j\u00eddla.<\/strong> Potrava m\u00edrn\u011b zpomaluje vst\u0159eb\u00e1v\u00e1n\u00ed, ale nesni\u017euje celkov\u00e9 mno\u017estv\u00ed absorbovan\u00e9 l\u00e1tky.<\/li>\n<li><strong>Udr\u017eujte terapeutickou d\u00e1vku po dobu 4\u20138 t\u00fddn\u016f<\/strong> p\u0159ed posouzen\u00edm kognitivn\u00edho \u00fa\u010dinku. Efekty se postupn\u011b kumuluj\u00ed sp\u00ed\u0161e ne\u017e aby zp\u016fsobovaly akutn\u00ed zm\u011bnu v ment\u00e1ln\u00ed jasnosti.<\/li>\n<li><strong>U kortik\u00e1ln\u00edho myoklonu zvy\u0161ujte d\u00e1vku postupn\u011b po dobu 1\u20132 t\u00fddn\u016f<\/strong> a\u017e do dosa\u017een\u00ed adekv\u00e1tn\u00ed kontroly. \u010casto jsou pot\u0159eba d\u00e1vky 16\u201324 g\/den, kter\u00e9 jsou dob\u0159e tolerov\u00e1ny.<\/li>\n<li><strong>Vyhn\u011bte se ve\u010dern\u00edmu d\u00e1vkov\u00e1n\u00ed<\/strong> pokud m\u00e1te sklon k nespavosti \u2014 piracetam m\u016f\u017ee b\u00fdt m\u00edrn\u011b stimuluj\u00edc\u00ed.<\/li>\n<li><strong>Informujte ka\u017ed\u00e9ho p\u0159edepisuj\u00edc\u00edho l\u00e9ka\u0159e.<\/strong> Interakce s thyroidn\u00edm hormonem je jedin\u00e1 klinicky v\u00fdznamn\u00e1.<\/li>\n<li><strong>V\u011bt\u0161ina pacient\u016f m\u016f\u017ee l\u00e9\u010dbu ukon\u010dit bez postupn\u00e9ho sni\u017eov\u00e1n\u00ed d\u00e1vek.<\/strong> P\u0159i kognitivn\u00edm u\u017eit\u00ed. U kortik\u00e1ln\u00edho myoklonu sni\u017eujte d\u00e1vky pod odborn\u00fdm dohledem, abyste p\u0159ede\u0161li n\u00e1vratu myoklonu.<\/li>\n<\/ol>\n<h2 class=\"wp-block-heading\">Vedlej\u0161\u00ed \u00fa\u010dinky Cerecetamu<\/h2>\n<p><strong>\u010cast\u00e9 (\u010dasto z\u00e1visl\u00e9 na d\u00e1vce, obvykle m\u00edrn\u00e9):<\/strong><\/p>\n<ul>\n<li>Nespavost, m\u00edrn\u00e9 rozru\u0161en\u00ed<\/li>\n<li>Podr\u00e1\u017ed\u011bnost, hyperkineze (zejm\u00e9na u star\u0161\u00edch pacient\u016f a d\u011bt\u00ed)<\/li>\n<li>Bolest hlavy<\/li>\n<li>P\u0159\u00edr\u016fstek hmotnosti (~5 % pacient\u016f)<\/li>\n<li>Pr\u016fjem<\/li>\n<li>Ospalost (paradoxn\u00ed, m\u00e9n\u011b \u010dast\u00e1 ne\u017e nespavost)<\/li>\n<\/ul>\n<p><strong>M\u00e9n\u011b \u010dast\u00e9, ale d\u016fle\u017eit\u00e9:<\/strong><\/p>\n<ul>\n<li>Zm\u011bny n\u00e1lady, \u00fazkost, deprese (vz\u00e1cn\u00e9)<\/li>\n<li>Z\u00e1vrat\u011b<\/li>\n<li>Astenie<\/li>\n<li>Sexu\u00e1ln\u00ed poruchy (vz\u00e1cn\u00e9)<\/li>\n<li>Zv\u00fd\u0161en\u00e1 krv\u00e1civost \u2014 piracetam m\u00edrn\u011b inhibuje agregaci trombocyt\u016f<\/li>\n<\/ul>\n<p><strong>Vz\u00e1cn\u00e9, ale vy\u017eaduj\u00edc\u00ed l\u00e9ka\u0159skou pomoc:<\/strong><\/p>\n<ul>\n<li>Z\u00e1va\u017en\u00e1 vyr\u00e1\u017eka nebo angioed\u00e9m (p\u0159ecitliv\u011blost)<\/li>\n<li>Zhor\u0161en\u00ed preexistuj\u00edc\u00ed Huntingtonovy chorey<\/li>\n<li>Z\u00e1va\u017en\u00e9 krv\u00e1civ\u00e9 p\u0159\u00edhody u pacient\u016f s poruchami sr\u00e1\u017elivosti nebo u\u017e\u00edvaj\u00edc\u00edch antikoagulancia<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Varov\u00e1n\u00ed a opat\u0159en\u00ed<\/h2>\n<ul>\n<li><strong>Porucha funkce ledvin:<\/strong> piracetam je 100% vylu\u010dov\u00e1n ledvinami. Upravte d\u00e1vkov\u00e1n\u00ed podle clearance kreatininu; vyvarujte se u\u017eit\u00ed p\u0159i CrCl &lt;30 ml\/min.<\/li>\n<li><strong>Krv\u00e1civost:<\/strong> piracetam inhibuje agregaci trombocyt\u016f. Opatrnost u pacient\u016f s peptick\u00fdm v\u0159edem, z\u00e1va\u017en\u00fdm krv\u00e1cen\u00edm, po ned\u00e1vn\u00e9 operaci, u\u017e\u00edvaj\u00edc\u00edch antikoagulancia nebo antiagregancia.<\/li>\n<li><strong>Huntingtonova choroba:<\/strong> vyvarujte se \u2014 piracetam m\u016f\u017ee u n\u011bkter\u00fdch pacient\u016f zhor\u0161it choreu.<\/li>\n<li><strong>Star\u0161\u00ed pacienti:<\/strong> hyperkineze, agitace a nespavost jsou \u010dast\u011bj\u0161\u00ed; za\u010dn\u011bte na spodn\u00ed hranici d\u00e1vkov\u00e9ho rozmez\u00ed.<\/li>\n<li><strong>T\u011bhotenstv\u00ed:<\/strong> bezpe\u010dnost nebyla stanovena. Vyhn\u011bte se u\u017e\u00edv\u00e1n\u00ed, pokud p\u0159\u00ednos jasn\u011b nep\u0159ev\u00e1\u017e\u00ed nezn\u00e1m\u00e9 riziko \u2014 u\u017e\u00edvejte pouze pod odborn\u00fdm dohledem.<\/li>\n<li><strong>Kojen\u00ed:<\/strong> piracetam se vylu\u010duje do mate\u0159sk\u00e9ho ml\u00e9ka; kojen\u00ed p\u0159eru\u0161te nebo se mu vyhn\u011bte.<\/li>\n<li><strong>Pl\u00e1novan\u00fd chirurgick\u00fd v\u00fdkon:<\/strong> piracetam p\u0159eru\u0161te 1 t\u00fdden p\u0159ed operac\u00ed, je-li to mo\u017en\u00e9, kv\u016fli vlivu na krevn\u00ed desti\u010dky.<\/li>\n<li><strong>\u0158\u00edzen\u00ed vozidla:<\/strong> ob\u010das se vyskytuje ospalost; ne\u0159i\u010fte, dokud nev\u00edte, jak l\u00e9k na v\u00e1s p\u016fsob\u00ed.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Kontraindikace \u2014 Kdo by NEM\u011aL u\u017e\u00edvat Cerecetam<\/h2>\n<ul>\n<li>Zn\u00e1m\u00e1 p\u0159ecitliv\u011blost na piracetam, pyrrolidonov\u00e9 deriv\u00e1ty nebo jakoukoli pomocnou l\u00e1tku<\/li>\n<li>Kone\u010dn\u00e9 stadium ren\u00e1ln\u00edho selh\u00e1n\u00ed (ClCr &lt;20 ml\/min)<\/li>\n<li>Mozkov\u00e9 krv\u00e1cen\u00ed (akutn\u00ed)<\/li>\n<li>Huntingtonova choroba<\/li>\n<li>T\u011bhotenstv\u00ed a kojen\u00ed (pokud odborn\u00edk nerozhodne, \u017ee p\u0159\u00ednos p\u0159ev\u00e1\u017e\u00ed riziko)<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Interakce s l\u00e9\u010divy<\/h2>\n<table style=\"border-collapse:collapse;width:100%;margin:12px 0;\">\n<thead>\n<tr style=\"background:#2c7cb0;color:#fff;\">\n<th style=\"padding:10px;border:1px solid #ddd;text-align:left;\">Kombinujte s<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;text-align:left;\">\u00da\u010dinek<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;text-align:left;\">Co d\u011blat<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Hormony \u0161t\u00edtn\u00e9 \u017el\u00e1zy (tyroxin, T3)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Kazuistiky zmatenosti, t\u0159esu a poruch sp\u00e1nku<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">U\u017e\u00edvejte opatrn\u011b; sledujte p\u0159\u00edznaky podobn\u00e9 adrenergn\u00edm \u00fa\u010dink\u016fm.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Warfarin nebo jin\u00e1 antikoagulancia<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Aditivn\u00ed krv\u00e1civost (piracetam m\u00edrn\u011b inhibuje trombocyty)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Monitorujte INR nebo krv\u00e1cen\u00ed; samotn\u00fd piracetam neprolonguje INR, ale m\u016f\u017ee zhor\u0161it krv\u00e1cen\u00ed zp\u016fsoben\u00e9 antikoagulancii.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Aspirin, NSAID, antiagregancia<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Aditivn\u00ed antiagrega\u010dn\u00ed \u00fa\u010dinek<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Opatrnost; u pacient\u016f s anamn\u00e9zou krv\u00e1cen\u00ed kombinaci rad\u011bji vynechejte.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Alkohol<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">\u017d\u00e1dn\u00e1 v\u00fdznamn\u00e1 farmakokinetick\u00e1 interakce; minim\u00e1ln\u00ed aditivn\u00ed \u00fa\u010dinky na CNS<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Obecn\u011b bezpe\u010dn\u00e9 p\u0159i m\u00edrn\u00e9m u\u017e\u00edv\u00e1n\u00ed.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Jin\u00e9 AMPA-moduluj\u00edc\u00ed l\u00e1tky<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Teoretick\u00e9 aditivn\u00ed \u00fa\u010dinky<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Dohled specialisty.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Karbamazepin, fenytoin, valpro\u00e1t sodn\u00fd<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">\u017d\u00e1dn\u00e1 v\u00fdznamn\u00e1 interakce<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Pou\u017e\u00edv\u00e1 se spole\u010dn\u011b u myoklonick\u00fdch syndrom\u016f.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2 class=\"wp-block-heading\">Pokyny k uchov\u00e1v\u00e1n\u00ed<\/h2>\n<ul>\n<li>Skladujte p\u0159i pokojov\u00e9 teplot\u011b, <strong>15\u201330\u00b0C<\/strong>. Chra\u0148te p\u0159ed vlhkost\u00ed.<\/li>\n<li>Tablety uchov\u00e1vejte v p\u016fvodn\u00edm blistru a\u017e do pou\u017eit\u00ed.<\/li>\n<li>Neskladujte v koupeln\u011b.<\/li>\n<li>Uchov\u00e1vejte mimo dosah d\u011bt\u00ed.<\/li>\n<li>Nepou\u017e\u00edvejte po uplynut\u00ed data expirace.<\/li>\n<li>Nepou\u017eit\u00fd l\u00e9k vra\u0165te do l\u00e9k\u00e1rny k odborn\u00e9 likvidaci.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Souvisej\u00edc\u00ed alternativy na MedsBase<\/h2>\n<p>Dal\u0161\u00ed l\u00e9ky skladem pro souvisej\u00edc\u00ed stavy:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/cs\/neurological-conditions-and-epilepsy\/\">Prohl\u00e9dn\u011bte si v\u0161echny neurologick\u00e9 a antiepileptick\u00e9 l\u00e9ky<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/anti-migraine\/\">Prohl\u00e9dn\u011bte si l\u00e9ky proti migr\u00e9n\u011b<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/mental-health-and-psychiatric-medications\/\">Proch\u00e1zejte l\u00e9ky na du\u0161evn\u00ed zdrav\u00ed a psychiatrick\u00e9 l\u00e9ky<\/a><\/li>\n<\/ul>\n<h2 id=\"faqs\">\u010casto kladen\u00e9 dotazy<\/h2>\n<h3 class=\"wp-block-heading\">Jak dlouho trv\u00e1, ne\u017e Cerecetam za\u010dne \u00fa\u010dinkovat?<\/h3>\n<p><strong>Kognitivn\u00ed \u00fa\u010dinky se postupn\u011b projevuj\u00ed b\u011bhem 4\u20138 t\u00fddn\u016f<\/strong> p\u0159i terapeutick\u00e9 d\u00e1vce \u2014 nejedn\u00e1 se o l\u00e9k, kter\u00fd by poskytoval okam\u017eit\u00e9 zlep\u0161en\u00ed ment\u00e1ln\u00ed jasnosti b\u011bhem hodin. U <strong>kortik\u00e1ln\u00ed myoklonus<\/strong>,  lze pozorovat \u00fa\u010dinek b\u011bhem 1\u20132 t\u00fddn\u016f, jakmile d\u00e1vka dos\u00e1hne terapeutick\u00e9ho rozmez\u00ed (obvykle 7,2\u201324 g\/den). U <strong>af\u00e1zie po c\u00e9vn\u00ed mozkov\u00e9 p\u0159\u00edhod\u011b<\/strong>,  se zlep\u0161en\u00ed projevuje b\u011bhem 6\u201312 t\u00fddn\u016f spolu s logopedickou terapi\u00ed. Pokud po 8 t\u00fddnech nen\u00ed patrn\u00fd \u017e\u00e1dn\u00fd \u00fa\u010dinek, je vhodn\u00e9 zv\u00fd\u0161it d\u00e1vku nebo zvolit alternativn\u00ed terapii.<\/p>\n<h3 class=\"wp-block-heading\">Pro\u010d Cerecetam nem\u00e1 schv\u00e1len\u00ed FDA v USA?<\/h3>\n<p>Piracetam byl vyvinut v Belgii v 60. letech 20. stolet\u00ed a je des\u00edtky let licencov\u00e1n v Evrop\u011b, Asii a Latinsk\u00e9 Americe. P\u016fvodn\u00ed v\u00fdrobce nikdy nepo\u017e\u00e1dal o schv\u00e1len\u00ed FDA ve Spojen\u00fdch st\u00e1tech \u2014 \u010d\u00e1ste\u010dn\u011b proto, \u017ee n\u00e1klady na v\u00fdvoj by se nevr\u00e1tily, proto\u017ee piracetam vy\u0161el z patentov\u00e9 ochrany p\u0159edt\u00edm, ne\u017e se modern\u00ed proces schvalov\u00e1n\u00ed FDA ust\u00e1lil, a \u010d\u00e1ste\u010dn\u011b proto, \u017ee c\u00edlov\u00e9 parametry pro hodnocen\u00ed kognitivn\u00edho zlep\u0161en\u00ed nebyly v t\u00e9 dob\u011b dob\u0159e definov\u00e1ny. L\u00e9k z\u016fst\u00e1v\u00e1 uzn\u00e1van\u00fdm farmaceutick\u00fdm p\u0159\u00edpravkem s rozs\u00e1hl\u00fdmi dlouhodob\u00fdmi bezpe\u010dnostn\u00edmi \u00fadaji na trz\u00edch, kde je licencov\u00e1n.<\/p>\n<h3 class=\"wp-block-heading\">Je Cerecetam skute\u010dn\u00fd \u201cnootropikum\u201d?<\/h3>\n<p><strong>Piracetam je p\u016fvodn\u00ed l\u00e9k, pro kter\u00fd byl term\u00edn \u201cnootropikum\u201d vytvo\u0159en<\/strong> jeho spoluobjevitelem Corneliu Giurgeou v roce 1972. P\u016fvodn\u00ed definice vy\u017eadovala: zlep\u0161en\u00ed u\u010den\u00ed\/pam\u011bti, ochranu p\u0159ed po\u0161kozen\u00edm, velmi n\u00edzkou toxicitu, \u017e\u00e1dnou sedaci nebo stimulaci a absenci typick\u00fdch farmakologick\u00fdch vedlej\u0161\u00edch \u00fa\u010dink\u016f. Piracetam tuto definici spl\u0148uje. V sou\u010dasn\u00e9m pou\u017eit\u00ed byl term\u00edn \u201cnootropikum\u201d aplikov\u00e1n na mnoho dopl\u0148k\u016f stravy bez srovnateln\u00fdch d\u016fkaz\u016f; piracetam z\u016fst\u00e1v\u00e1 v samostatn\u00e9 kategorii jako regulovan\u00fd l\u00e9k na p\u0159edpis.<\/p>\n<h3 class=\"wp-block-heading\">Bude Cerecetam \u00fa\u010dinkovat u zdrav\u00fdch mlad\u00fdch dosp\u011bl\u00fdch, kte\u0159\u00ed cht\u011bj\u00ed kognitivn\u00ed zlep\u0161en\u00ed?<\/h3>\n<p><strong>D\u016fkazy jsou v t\u00e9to skupin\u011b nejslab\u0161\u00ed.<\/strong> V\u011bt\u0161ina klinick\u00fdch studi\u00ed prob\u00edh\u00e1 u star\u0161\u00edch dosp\u011bl\u00fdch, pacient\u016f po mrtvici nebo pacient\u016f s kognitivn\u00edm posti\u017een\u00edm \u2013 populace, u kter\u00fdch piracetam prokazuje jasn\u011bj\u0161\u00ed p\u0159\u00ednos. U zdrav\u00fdch mlad\u00fdch dosp\u011bl\u00fdch jsou kontrolovan\u00e9 studie vz\u00e1cn\u00e9 a \u00fa\u010dinek, pokud n\u011bjak\u00fd je, je skromn\u00fd. Piracetam nen\u00ed n\u00e1hradou za sp\u00e1nek, cvi\u010den\u00ed, hydrataci nebo stimula\u010dn\u00ed l\u00e9ky, pokud jsou tyto vhodn\u00e9.<\/p>\n<h3 class=\"wp-block-heading\">Jak\u00fd je rozd\u00edl mezi piracetamem a jin\u00fdmi racetamy?<\/h3>\n<p><strong>Piracetam<\/strong> je p\u016fvodn\u00ed racetam \u2013 nejni\u017e\u0161\u00ed \u00fa\u010dinnost, nejv\u00edce d\u016fkaz\u016f, nejdel\u0161\u00ed z\u00e1znam o bezpe\u010dnosti. <strong>Aniracetam<\/strong> je rozpustn\u00fd v tuc\u00edch, rychleji p\u016fsob\u00edc\u00ed, m\u00edrn\u011b v\u00edce anxiolytick\u00fd; <strong>oxiracetam<\/strong> je v\u00edce stimuluj\u00edc\u00ed; <strong>levetiracetam<\/strong> je strukturn\u011b p\u0159\u00edbuzn\u00fd antikonvulzivum s velmi odli\u0161nou farmakologi\u00ed a schv\u00e1len\u00edm FDA; <strong>brivaracetam<\/strong> je nov\u011bj\u0161\u00ed antikonvulzivum pro fok\u00e1ln\u00ed z\u00e1chvaty. Z t\u011bchto l\u00e1tek maj\u00ed pouze piracetam a levetiracetam v\u00fdznamn\u00e9 klinick\u00e9 d\u016fkazy u lid\u00ed; ostatn\u00ed se v\u011bt\u0161inou pou\u017e\u00edvaj\u00ed off-label nebo jako dopl\u0148ky stravy.<\/p>\n<h3 class=\"wp-block-heading\">Interaguje Cerecetam s m\u00fdmi l\u00e9ky na \u0161t\u00edtnou \u017el\u00e1zu?<\/h3>\n<p><strong>Existuj\u00ed kazuistiky<\/strong> zmatenosti, t\u0159esu a poruch sp\u00e1nku, kdy\u017e je piracetam kombinov\u00e1n s tyroxinem nebo T3, co\u017e nazna\u010duje mo\u017enou adrenergn\u00ed interakci. Mechanismus nen\u00ed objasn\u011bn. Pokud u\u017e\u00edv\u00e1te hormon\u00e1ln\u00ed substitu\u010dn\u00ed terapii \u0161t\u00edtn\u00e9 \u017el\u00e1zy, informujte sv\u00e9ho l\u00e9ka\u0159e p\u0159ed zah\u00e1jen\u00edm u\u017e\u00edv\u00e1n\u00ed piracetamu, sledujte v\u00fdskyt t\u0159esu, \u00fazkosti nebo poruch sp\u00e1nku a v p\u0159\u00edpad\u011b p\u0159\u00edznak\u016f sni\u017ete d\u00e1vku piracetamu.<\/p>\n<h3 class=\"wp-block-heading\">Zp\u016fsobuje Cerecetam p\u0159ib\u00edr\u00e1n\u00ed na v\u00e1ze?<\/h3>\n<p><strong>M\u00edrn\u00e9 p\u0159ib\u00fdv\u00e1n\u00ed na v\u00e1ze je hl\u00e1\u0161eno u p\u0159ibli\u017en\u011b 5 % pacient\u016f<\/strong>, \u010dast\u011bji u star\u0161\u00edch dosp\u011bl\u00fdch a p\u0159i vy\u0161\u0161\u00edch d\u00e1vk\u00e1ch (8 g\/den a v\u00edce). Mechanismus nen\u00ed jasn\u011b objasn\u011bn. Tento \u00fa\u010dinek je reverzibiln\u00ed po sn\u00ed\u017een\u00ed d\u00e1vky nebo vysazen\u00ed l\u00e9ku.<\/p>\n<h3 class=\"wp-block-heading\">M\u016f\u017ee se Cerecetam pou\u017e\u00edvat u d\u011bt\u00ed?<\/h3>\n<p><strong>Ano \u2014 piracetam je v Evrop\u011b schv\u00e1len pro l\u00e9\u010dbu dyslexie u d\u011bt\u00ed star\u0161\u00edch 7 let<\/strong> jako dopln\u011bk strukturovan\u00e9 n\u00e1pravn\u00e9 v\u00fduky. Typick\u00e1 d\u00e1vka je 3,2 g\/den ve 2 rozd\u011blen\u00fdch d\u00e1vk\u00e1ch. Pou\u017e\u00edv\u00e1 se tak\u00e9 u pediatrick\u00e9 kortik\u00e1ln\u00ed myoklonie a posttraumatick\u00fdch kognitivn\u00edch n\u00e1sledk\u016f. Hyperkineze a podr\u00e1\u017ed\u011bnost jsou u d\u011bt\u00ed m\u00edrn\u011b \u010dast\u011bj\u0161\u00ed; doporu\u010duje se pe\u010dliv\u00e9 sledov\u00e1n\u00ed rodi\u010di.<\/p>\n<h3 class=\"wp-block-heading\">Je Cerecetam n\u00e1vykov\u00fd?<\/h3>\n<p><strong>Ne.<\/strong> Piracetam nem\u00e1 aktivitu na GABA receptorech, \u017e\u00e1dnou opioidn\u00ed aktivitu, \u017e\u00e1dn\u00fd stimula\u010dn\u00ed \u00fa\u010dinek a nen\u00ed dokumentov\u00e1n potenci\u00e1l pro toleranci nebo z\u00e1vislost. Lze jej vysadit bez strukturovan\u00e9ho postupn\u00e9ho sni\u017eov\u00e1n\u00ed d\u00e1vky u kognitivn\u00edch indikac\u00ed, a\u010dkoli u kortik\u00e1ln\u00edho myoklonu je postupn\u00e1 redukce rozumn\u00e1, aby se p\u0159ede\u0161lo pr\u016flomov\u00fdm p\u0159\u00edznak\u016fm.<\/p>\n<h3 class=\"wp-block-heading\">Mohu p\u00edt alkohol p\u0159i u\u017e\u00edv\u00e1n\u00ed Cerecetamu?<\/h3>\n<p><strong>Ano, s m\u00edrou.<\/strong> Neexistuje \u017e\u00e1dn\u00e1 specifick\u00e1 farmakokinetick\u00e1 interakce a nen\u00ed dokumentov\u00e1no zv\u00fd\u0161en\u00e9 riziko. Nadm\u011brn\u00e9 pit\u00ed alkoholu z\u016fst\u00e1v\u00e1 samo o sob\u011b \u0161kodliv\u00e9 pro kognici. N\u011bkte\u0159\u00ed pacienti u\u017e\u00edvaj\u00ed piracetam off-label po akutn\u00ed intoxikaci na z\u00e1klad\u011b teorie, \u017ee zlep\u0161uje zotaven\u00ed; d\u016fkazy pro toto pou\u017eit\u00ed jsou omezen\u00e9.<\/p>\n<h3 class=\"wp-block-heading\">Kde se Cerecetam vyr\u00e1b\u00ed?<\/h3>\n<p>Cerecetam je dod\u00e1v\u00e1n spole\u010dnost\u00ed <strong>v\u00fdrobce certifikovan\u00e9ho WHO-GMP<\/strong> a je bioekvivalentn\u00ed origin\u00e1ln\u00edmu piracetamu (Nootropil\u00ae, UCB) ve stejn\u00e9 miligramov\u00e9 s\u00edle. Certifik\u00e1ty anal\u00fdzy \u0161ar\u017e\u00ed jsou k dispozici na vy\u017e\u00e1d\u00e1n\u00ed.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h3 class=\"wp-block-heading\">Souvisej\u00edc\u00ed alternativy<\/h3>\n<p>Dal\u0161\u00ed produkty v <strong>Chronick\u00e1 onemocn\u011bn\u00ed<\/strong> kter\u00e9 z\u00e1kazn\u00edci tak\u00e9 prohl\u00ed\u017eej\u00ed:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/cs\/lonitab\/\">Lonitab<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/medrol\/\">Medrol<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/gabatop\/\">Gabatop<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/indicid-75-sr\/\">Indicid-75 SR<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/cs\/sazo\/\">Sazo<\/a><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 Zlep\u0161uje kognitivn\u00ed funkce<br \/>\n\u2705 Zlep\u0161uje pam\u011b\u0165<br \/>\n\u2705 Zvy\u0161uje ment\u00e1ln\u00ed jasnost<br \/>\n\u2705 Zvy\u0161uje soust\u0159ed\u011bn\u00ed a pozornost<br \/>\n\u2705 Podporuje zdrav\u00ed mozku<\/p>\n<p>Cerecetam obsahuje Piracetam.<\/p>","protected":false},"featured_media":60109,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3141,3223,3468],"product_tag":[4811,4800],"class_list":{"0":"post-60108","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-category-overview","7":"product_cat-chronic-conditions","8":"product_cat-neurological-conditions-and-epilepsy","9":"product_tag-cerecetam","10":"product_tag-piracetam","12":"first","13":"instock","14":"shipping-taxable","15":"purchasable","16":"product-type-variable","17":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product\/60108","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/comments?post=60108"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/media\/60109"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/media?parent=60108"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_brand?post=60108"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_cat?post=60108"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_tag?post=60108"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}